Evidence map›Paper›PMID 28256434›Full record

ArticleParkinsonism & related disorders2017

Pathologic correlates of supranuclear gaze palsy with parkinsonism.

W R W Martin, J Hartlein, B A Racette, N Cairns, J S Perlmutter

Abstract read
In one paragraph

Article in Parkinsonism & related disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Is Levodopa Response a Valid Indicator of Parkinson's Disease?Movement disorders : official journal of the Movement Disorder Society · 2021
    Article
  5. Article
  6. Review
  7. Progressive Supranuclear Palsy: an Update.Current neurology and neuroscience reports · 2018
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

W R W MartinNeurology, University of Alberta, Edmonton, AB, Canada. Electronic address: wayne.martin@ualberta.ca.
J HartleinNeurology, Washington University in St. Louis, St. Louis, MO, USA.
B A RacetteNeurology, Washington University in St. Louis, St. Louis, MO, USA; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa.
N CairnsNeurology, Washington University in St. Louis, St. Louis, MO, USA; Pathology, Washington University in St. Louis, St. Louis, MO, USA.
J S PerlmutterNeurology, Washington University in St. Louis, St. Louis, MO, USA; Radiology, Neuroscience, Physical Therapy and Occupational Therapy, Washington University in St. Louis, St. Louis, MO, USA.
Washington University in St. Louis · USUniversity of Alberta · CAUniversity of the Witwatersrand · ZA

Funding

INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASER01NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2011 to 2021
$8.2M
MECHANISMS OF DEEP BRAIN STIMULATIONR01NS041509 · NINDS · WASHINGTON UNIVERSITY · PI PERLMUTTER, JOEL SYNES · 2001 to 2015
$6.8M
VALIDATION OF NEUROIMAGING BIOMARKERS FOR NIGROSTRIATAL NEURONSR01NS058714 · NINDS · WASHINGTON UNIVERSITY · PI PERLMUTTER, JOEL SYNES · 2008 to 2016
$4.4M
Investigations of Dementia in Parkinson DiseaseRF1NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2023 to 2023
$2.3M
Epidemiology and Biomarkers of Parkinsonism in WeldersK24ES017765 · NIEHS · WASHINGTON UNIVERSITY · PI RACETTE, BRAD A · 2009 to 2018
$1.5M
Neurodegenerative consequences of PanK2 mutationsK08NS048924 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T · 2004 to 2008
$878k
Parkinson's Disease Neuroprotection Trial: Clinical CenterU10NS044426 · NINDS · UNIVERSITY OF ALBERTA · PI MARTIN, W. R. WAYNE · 2002 to 2014
$507k
NIEHS NIH HHS K24 ES017765NINDS NIH HHS K08 NS048924NINDS NIH HHS R01 NS041509NINDS NIH HHS R01 NS058714NINDS NIH HHS R01 NS075321NINDS NIH HHS RF1 NS075321NINDS NIH HHS U10 NS044426
6 · The paper itself

Abstract

introductionSupranuclear gaze palsy (SGP) is a classic clinical feature of progressive supranuclear palsy (PSP) but is not specific for this diagnosis and has been reported to occur in several other neurodegenerative parkinsonian conditions. Our objective was to evaluate the association between SGP and autopsy-proven diagnoses in a large population of patients with parkinsonism referred to a tertiary movement disorders clinic.

methodsWe reviewed clinical and autopsy data maintained in an electronic medical record from all patients seen in the Movement Disorders Clinic at Washington University, St. Louis between 1996 and 2015. All patients with parkinsonism from this population who had subsequent autopsy confirmation of diagnosis underwent further analysis.

results221 unique parkinsonian patients had autopsy-proven diagnoses, 27 of whom had SGP documented at some point during their illness. Major diagnoses associated with SGP were: PSP (9 patients), Parkinson disease (PD) (10 patients), multiple system atrophy (2 patients), corticobasal degeneration (2 patients), Creutzfeld-Jakob disease (1 patient) and Huntington disease (1 patient). In none of the diagnostic groups was the age of onset or disease duration significantly different between cases with SGP and those without SGP. In the PD patients, the UPDRS motor score differed significantly between groups (p = 0.01) with the PD/SGP patients having greater motor deficit than those without SGP.

conclusionAlthough a common feature of PSP, SGP is not diagnostic for this condition and can be associated with other neurodegenerative causes of parkinsonism including PD.

Indexed as

AgedAged, 80 and overAge of OnsetAutopsyDatabases, FactualFemaleHumansMaleMiddle AgedParkinson DiseaseRetrospective StudiesSupranuclear Palsy, ProgressiveParkinson diseaseParkinsonismProgressive supranuclear palsySupranuclear gaze palsy

Identifiers

PMID28256434
PMCPMC5397329
OpenAlexW2589496922

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.